Cara Therapeutics (CARA)

Cara Therapeutics (CARA) Financial Statements


Cara Therapeutics Financial Overview

Cara Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.255; its P/E ratio is -0.33; Cara Therapeutics is scheduled to report earnings on August 5, 2024, and the estimated EPS forecast is $-0.27. See an overview of income statement, balance sheet, and cash flow financials.
Sep 23Jun 23Mar 23Dec 22Sep 22
Income Statement-
Total Revenue$ 4.87M$ 5.41M$ 6.17M$ 3.26M$ 10.81M
Gross Profit$ 4.87M$ 6.93M$ 6.17M$ 3.26M$ 7.76M
EBIT$ -24.92M$ -28.64M$ -26.66M$ -30.34M$ -23.84M
EBITDA$ -24.50M$ -28.16M$ -26.33M$ -30.14M$ -23.78M
Net Income Common Stockholders$ -28.03M$ -31.48M$ -26.66M$ -30.34M$ -23.18M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 78.54M$ 95.10M$ 47.80M$ 64.15M$ 155.61M
Total Assets$ 115.34M$ 134.39M$ 153.28M$ 182.24M$ 213.51M
Total Debt$ 7.31M$ 982.00K$ 77.42M$ 94.93M$ 2.37M
Net Debt$ -71.23M$ -94.12M$ 29.62M$ 30.78M$ -153.24M
Total Liabilities$ 29.70M$ 25.46M$ 92.64M$ 116.47M$ 28.69M
Stockholders Equity$ 85.64M$ 108.93M$ 136.60M$ 158.78M$ 184.82M
Cash Flow-
Free Cash Flow$ -19.97M$ -20.45M$ -34.62M$ -23.51M$ -25.19M
Operating Cash Flow$ -19.64M$ -20.45M$ -34.62M$ -23.51M$ -25.19M
Investing Cash Flow$ 23.16M$ 32.80M$ 17.71M$ 44.42M$ 21.18M
Financing Cash Flow$ 1.12M-$ 560.00K$ 22.00K$ 104.00K
Currency in USD

Cara Therapeutics Earnings and Revenue History

Cara Therapeutics Debt to Assets

Cara Therapeutics Cash Flow

Cara Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis